Skip to main content

Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis

Inflammation Research volume 65, pages 347–354 (2016)Cite this article

Abstract

Introduction

Inflammatory bone resorption causes progressive joint destruction which ultimately leads to functional disability in rheumatoid arthritis (RA). The primary cell responsible for bone resorption is the osteoclast, which means it is a potential therapeutic target against bone destruction. In fact, experimental and clinical findings suggest that blockade of osteoclast differentiation and function is highly effective in inhibiting bone destruction in RA.

Discussion and conclusion

In this report, we show several lines of experimental evidence which suggest that a variety of Ca2+ channels are essential in osteoclast differentiation and function, and present a hypothesis that modulation of Ca2+ channels is a highly effective therapeutic strategy in preventing osteoclast-induced structural damage in RA.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Kleyer A, Schett G. Arthritis and bone loss: a hen and egg story. Curr Opin Rheumatol. 2014;26(1):80–4. doi:10.1097/BOR.0000000000000007.

    CAS  Article  PubMed  Google Scholar 

  2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi:10.1136/annrheumdis-2013-204573.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2010;22(3):321–9. doi:10.1097/BOR.0b013e328337bd01.

    CAS  Article  PubMed  Google Scholar 

  4. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7(11):639–52. doi:10.1038/nrrheum.2011.145.

    CAS  Article  PubMed  Google Scholar 

  5. Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2009;68(12):1898–901. doi:10.1136/ard.2008.106484.

    CAS  Article  PubMed  Google Scholar 

  6. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29(4):403–40. doi:10.1210/er.2007-0038.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther. 2007;9(1):203. doi:10.1186/ar2110.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69(5):872–5. doi:10.1136/ard.2009.112920.

    CAS  Article  PubMed  Google Scholar 

  9. Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res. 2010;62(4):537–44. doi:10.1002/acr.20172.

    Article  Google Scholar 

  10. Schett G. Erosive arthritis. Arthritis Res Ther. 2007;9(Suppl 1):S2. doi:10.1186/ar2166.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol. 2014;5:511. doi:10.3389/fimmu.2014.00511.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kajiya H. Calcium signaling in osteoclast differentiation and bone resorption. Adv Exp Med Biol. 2012;740:917–32. doi:10.1007/978-94-007-2888-2_41.

    CAS  Article  PubMed  Google Scholar 

  13. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004;428(6984):758–63. doi:10.1038/nature02444.

    CAS  Article  PubMed  Google Scholar 

  14. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008;132(5):794–806. doi:10.1016/j.cell.2007.12.037.

    CAS  Article  PubMed  Google Scholar 

  15. Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med. 2006;12(12):1410–6. doi:10.1038/nm1515.

    CAS  Article  PubMed  Google Scholar 

  16. Robinson LJ, Blair HC, Barnett JB, Zaidi M, Huang CL. Regulation of bone turnover by calcium-regulated calcium channels. Ann N Y Acad Sci. 2010;1192:351–7. doi:10.1111/j.1749-6632.2009.05219.x.

    CAS  Article  PubMed  Google Scholar 

  17. Kuroda Y, Hisatsune C, Nakamura T, Matsuo K, Mikoshiba K. Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis. Proc Natl Acad Sci USA. 2008;105(25):8643–8. doi:10.1073/pnas.0800642105.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Yaroslavskiy BB, Sharrow AC, Wells A, Robinson LJ, Blair HC. Necessity of inositol (1,4,5)-trisphosphate receptor 1 and mu-calpain in NO-induced osteoclast motility. J Cell Sci. 2007;120(Pt 16):2884–94. doi:10.1242/jcs.004184.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Feske S. ORAI1 and STIM1 deficiency in human and mice: roles of store-operated Ca2+ entry in the immune system and beyond. Immunol Rev. 2009;231(1):189–209. doi:10.1111/j.1600-065X.2009.00818.x.

    CAS  Article  PubMed  Google Scholar 

  20. Collins HE, Zhu-Mauldin X, Marchase RB, Chatham JC. STIM1/Orai1-mediated SOCE: current perspectives and potential roles in cardiac function and pathology. Am J Physiol Heart Circ Physiol. 2013;305(4):H446–58. doi:10.1152/ajpheart.00104.2013.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Kim MS, Yang YM, Son A, Tian YS, Lee SI, Kang SW, et al. RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem. 2010;285(10):6913–21. doi:10.1074/jbc.M109.051557.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Hwang SY, Putney JW. Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1. FASEB J. 2012;26(4):1484–92. doi:10.1096/fj.11-194399.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Zhou Y, Lewis TL, Robinson LJ, Brundage KM, Schafer R, Martin KH, et al. The role of calcium release activated calcium channels in osteoclast differentiation. J Cell Physiol. 2011;226(4):1082–9. doi:10.1002/jcp.22423.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. Robinson LJ, Mancarella S, Songsawad D, Tourkova IL, Barnett JB, Gill DL, et al. Gene disruption of the calcium channel Orai1 results in inhibition of osteoclast and osteoblast differentiation and impairs skeletal development. Lab Investig. 2012;92(7):1071–83. doi:10.1038/labinvest.2012.72.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. Nilius B, Voets T, Peters J. TRP channels in disease. Sci STKE. 2005;2005(295):re8. doi:10.1126/stke.2952005re8.

    PubMed  Google Scholar 

  26. Hoenderop JG, van Leeuwen JP, van der Eerden BC, Kersten FF, van der Kemp AW, Merillat AM, et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Investig. 2003;112(12):1906–14. doi:10.1172/JCI19826.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. van der Eerden BC, Hoenderop JG, de Vries TJ, Schoenmaker T, Buurman CJ, Uitterlinden AG, et al. The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption. Proc Natl Acad Sci USA. 2005;102(48):17507–12. doi:10.1073/pnas.0505789102.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Chamoux E, Bisson M, Payet MD, Roux S. TRPV-5 mediates a receptor activator of NF-kappaB (RANK) ligand-induced increase in cytosolic Ca2+ in human osteoclasts and down-regulates bone resorption. J Biol Chem. 2010;285(33):25354–62. doi:10.1074/jbc.M109.075234.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. Chen F, Ouyang Y, Ye T, Ni B, Chen A. Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel. J Cell Biochem. 2014;115(4):651–8. doi:10.1002/jcb.24700.

    CAS  Article  PubMed  Google Scholar 

  30. Mizoguchi F, Mizuno A, Hayata T, Nakashima K, Heller S, Ushida T, et al. Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone loss. J Cell Physiol. 2008;216(1):47–53. doi:10.1002/jcp.21374.

    CAS  Article  PubMed  Google Scholar 

  31. Masuyama R, Vriens J, Voets T, Karashima Y, Owsianik G, Vennekens R, et al. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab. 2008;8(3):257–65. doi:10.1016/j.cmet.2008.08.002.

    CAS  Article  PubMed  Google Scholar 

  32. Masuyama R, Mizuno A, Komori H, Kajiya H, Uekawa A, Kitaura H, et al. Calcium/calmodulin-signaling supports TRPV4 activation in osteoclasts and regulates bone mass. J Bone Mineral Res. 2012;27(8):1708–21. doi:10.1002/jbmr.1629.

    CAS  Article  Google Scholar 

  33. Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone. 2009;44(3):476–84. doi:10.1016/j.bone.2008.10.056.

    CAS  Article  PubMed  Google Scholar 

  34. Idris AI, Landao-Bassonga E, Ralston SH. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone. 2010;46(4):1089–99. doi:10.1016/j.bone.2010.01.368.

    CAS  Article  PubMed  Google Scholar 

  35. Rossi F, Bellini G, Torella M, Tortora C, Manzo I, Giordano C, et al. The genetic ablation or pharmacological inhibition of TRPV1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice. Br J Pharmacol. 2014;171(10):2621–30. doi:10.1111/bph.12542.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. Kajiya H, Okamoto F, Nemoto T, Kimachi K, Toh-Goto K, Nakayana S, et al. RANKL-induced TRPV2 expression regulates osteoclastogenesis via calcium oscillations. Cell Calcium. 2010;48(5):260–9. doi:10.1016/j.ceca.2010.09.010.

    CAS  Article  PubMed  Google Scholar 

  37. Kajiya H, Okamoto F, Fukushima H, Takada K, Okabe K. Mechanism and role of high-potassium-induced reduction of intracellular Ca2+ concentration in rat osteoclasts. Am J Physiol Cell Physiol. 2003;285(2):C457–66. doi:10.1152/ajpcell.00033.2003.

    CAS  Article  PubMed  Google Scholar 

  38. Noh AL, Park H, Zheng T, Ha HI, Yim M. L-type Ca(2+) channel agonist inhibits RANKL-induced osteoclast formation via NFATc1 down-regulation. Life Sci. 2011;89(5–6):159–64. doi:10.1016/j.lfs.2011.05.009.

    CAS  Article  PubMed  Google Scholar 

  39. Datta HK, Horrocks BR. Mechanisms of calcium disposal from osteoclastic resorption hemivacuole. J Endocrinol. 2003;176(1):1–5.

    CAS  Article  PubMed  Google Scholar 

  40. Miyauchi A, Hruska KA, Greenfield EM, Duncan R, Alvarez J, Barattolo R, et al. Osteoclast cytosolic calcium, regulated by voltage-gated calcium channels and extracellular calcium, controls podosome assembly and bone resorption. J Cell Biol. 1990;111(6 Pt 1):2543–52.

    CAS  Article  PubMed  Google Scholar 

  41. Itoh Y, Hatano N, Hayashi H, Onozaki K, Miyazawa K, Muraki K. An environmental sensor, TRPV4 is a novel regulator of intracellular Ca2+ in human synoviocytes. Am J Physiol Cell Physiol. 2009;297(5):C1082–90. doi:10.1152/ajpcell.00204.2009.

    CAS  Article  PubMed  Google Scholar 

  42. Kochukov MY, McNearney TA, Yin H, Zhang L, Ma F, Ponomareva L, et al. Tumor necrosis factor-alpha (TNF-alpha) enhances functional thermal and chemical responses of TRP cation channels in human synoviocytes. Mol Pain. 2009;5:49. doi:10.1186/1744-8069-5-49.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Laragione T, Cheng KF, Tanner MR, He M, Beeton C, Al-Abed Y, et al. The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. Clin Immunol. 2015;158(2):183–92. doi:10.1016/j.clim.2015.04.001.

    CAS  Article  PubMed  Google Scholar 

  44. Phan MN, Leddy HA, Votta BJ, Kumar S, Levy DS, Lipshutz DB, et al. Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes. Arthritis Rheum. 2009;60(10):3028–37. doi:10.1002/art.24799.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. Clark AL, Votta BJ, Kumar S, Liedtke W, Guilak F. Chondroprotective role of the osmotically sensitive ion channel transient receptor potential vanilloid 4: age- and sex-dependent progression of osteoarthritis in Trpv4-deficient mice. Arthritis Rheum. 2010;62(10):2973–83. doi:10.1002/art.27624.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. Muramatsu S, Wakabayashi M, Ohno T, Amano K, Ooishi R, Sugahara T, et al. Functional gene screening system identified TRPV4 as a regulator of chondrogenic differentiation. J Biol Chem. 2007;282(44):32158–67. doi:10.1074/jbc.M706158200.

    CAS  Article  PubMed  Google Scholar 

  47. Yoo SA, Park BH, Park GS, Koh HS, Lee MS, Ryu SH, et al. Calcineurin is expressed and plays a critical role in inflammatory arthritis. J Immunol. 2006;177(4):2681–90.

    CAS  Article  PubMed  Google Scholar 

  48. Lai NS, Yu CL, Yin WY, Yu HC, Huang HB, Tung CH, et al. Combination of nifedipine and subtherapeutic dose of cyclosporin additively suppresses mononuclear cells activation of patients with rheumatoid arthritis and normal individuals via Ca(2+)-calcineurin-nuclear factor of activated T cells pathway. Clin Exp Immunol. 2012;168(1):78–86. doi:10.1111/j.1365-2249.2012.04563.x.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. Liu S, Watanabe S, Shudou M, Kuno M, Miura H, Maeyama K. Upregulation of store-operated Ca(2+) entry in the naive CD4(+) T cells with aberrant cytokine releasing in active rheumatoid arthritis. Immunol Cell Biol. 2014;92(9):752–60. doi:10.1038/icb.2014.45.

    CAS  Article  PubMed  Google Scholar 

  50. Adamopoulos IE, Tessmer M, Chao CC, Adda S, Gorman D, Petro M, et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol. 2011;187(2):951–9. doi:10.4049/jimmunol.1003986.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. Dixit N, Wu DJ, Belgacem YH, Borodinsky LN, Gershwin ME, Adamopoulos IE. Leukotriene B4 activates intracellular calcium and augments human osteoclastogenesis. Arthritis Res Ther. 2014;16(6):496. doi:10.1186/s13075-014-0496-y.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Liu S, Kiyoi T, Takemasa E, Maeyama K. Systemic lentivirus-mediated delivery of short hairpin RNA targeting calcium release-activated calcium channel 3 as gene therapy for collagen-induced arthritis. J Immunol. 2015;194(1):76–83. doi:10.4049/jimmunol.1401976.

    CAS  Article  PubMed  Google Scholar 

  53. Gao XH, Gao R, Tian YZ, McGonigle P, Barrett JE, Dai Y, et al. A store-operated calcium channel inhibitor attenuates collagen-induced arthritis. Br J Pharmacol. 2015;. doi:10.1111/bph.13104.

    PubMed Central  Google Scholar 

  54. Gao R, Gao X, Xia J, Tian Y, Barrett JE, Dai Y, et al. Potent analgesic effects of a store-operated calcium channel inhibitor. Pain. 2013;154(10):2034–44. doi:10.1016/j.pain.2013.06.017.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  55. Lin FF, Elliott R, Colombero A, Gaida K, Kelley L, Moksa A, et al. Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease. J Pharmacol Exp Ther. 2013;345(2):225–38. doi:10.1124/jpet.112.202788.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a Korea University Grant.

Author information

Affiliations

  1. Division of Rheumatology, College of Medicine, Korea University, 126-1, Anam-Dong 5-Ga, Sungbuk-Ku, Seoul, 136-705, South Korea

    Robin Park & Jong Dae Ji

Authors
  1. Robin Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jong Dae Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jong Dae Ji.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Responsible Editor: Jason J. McDougall.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Park, R., Ji, J.D. Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis. Inflamm. Res. 65, 347–354 (2016). https://doi.org/10.1007/s00011-016-0920-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-016-0920-7

Keywords

  • Osteoclast
  • Rheumatoid arthritis
  • Calcium channel
  • Inflammation